2020 NIAID Omnibus Broad Agency Announcement

Leading Research to Understand, Treat, and Prevent Infectious, Immunologic, and Allergic Diseases          Visit us on the Web 2020 NIAID Omnibus Broad Agency Announcement No. HHS-NIH-NIAID-BAA2020-1 contains five distinct research areas, including this one:   DAIT: Research Area 001 - Development of Radiation/Nuclear Medical Countermeasures (MCMs) The objective of this Research Area is to advance the development of candidate MCMs to reduce mortality and/or major morbidities associated with exposure to radiation from a radiological or nuclear incident. NIAID anticipates that research and development studies supported by this BAA will advance lead candidate MCMs toward eventual FDA approval or licensure to mitigate or treat radiation-induced injuries and thereby improve survival following a radiological event. Proposals are due April 9, 2020, by 3:00 PM Eastern Time Please address any inquiries to the NIAID Contracting Office point of contact shown in the solicitation. Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID). This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107